Výsledky vyhledávání

Tissue factor pathway inhibitor prevents thrombus formation on procoagulant subendothelial matrix

Autor: O. Nordfang, K S Sakariassen, M Thune-Wiiger, Anne Karin Lindahl, P M Sandset

Publikováno v: Blood Coagulation & Fibrinolysis. 5:755-760

The effect of recombinant tissue factor pathway inhibitor (rTFPI) on extracellular matrix procoagulant activity was studied in a human ex vivo model of thrombogenesis. Extracellular matrix of endotoxin stimulated endothelial cells perfused with human

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f7599744621293dbfb82a5f82161709
https://doi.org/10.1097/00001721-199410000-00012

Zobrazit plný text záznamu

Evidence that the C-terminus of tissue factor pathway inhibitor (TFPI) is essential for its in vitro and in vivo interaction with lipoproteins

Autor: O Nordfang, C. Bregengard, Sanne Valentin, P. Wildgoose

Publikováno v: Blood Coagulation & Fibrinolysis. 4:713-720

We have previously shown that the C-terminus of TFPI is essential for its anticoagulant activity. In the present study we have assessed the role of this region in the binding of TFPI to lipoproteins. We found that full length TFPI, but not C-terminal

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3a6084bb552e6b7e9386c39744fa6b76
https://doi.org/10.1097/00001721-199304050-00007

Zobrazit plný text záznamu

The effect of two-domain tissue factor pathway inhibitor on endotoxin-induced disseminated intravascular coagulation in rabbits

Autor: V. Diness, P. Wildgoose, O Nordfang, C. Bregengard, Ulla Hedner, O. Svendsen

Publikováno v: Blood Coagulation & Fibrinolysis. 4:699-706

Disseminated intravascular coagulation (DIC) is a common complication in sepsis, and may result from endotoxin-induced exposure of tissue factor on the surface of monocytes and endothelial cells. Tissue factor pathway inhibitor (TFPI) is a factor Xa-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d658615c98379990da5496e880026aa8
https://doi.org/10.1097/00001721-199304050-00005

Zobrazit plný text záznamu

Inhibitory properties of full-length and truncated recombinant tissue factor pathway inhibitor (TFPI). Evidence that the third Kunitz-type domain of TFPI is not essential for the inhibition of factor VIIa-tissue factor complexes on cell surfaces

Autor: Takayoshi Hamamoto, M. Yamamoto, J.-G. L. Petersen, O. Nordfang, Walter Kisiel, Donald C. Foster

Publikováno v: Journal of Biological Chemistry. 268:8704-8710

Human tissue factor pathway inhibitor (TFPI) is a plasma protease inhibitor that consists of three tandem Kunitz-type inhibitor domains flanked by a negatively charged NH2 terminus and a positively charged COOH-terminal tail. Previous studies have sh

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0474692a73f2a5002ec1bee6355959d7
https://doi.org/10.1016/s0021-9258(18)52932-x

Zobrazit plný text záznamu

Title Page / Table of Contents, Vol. 23, Supplement 1, 1993

Autor: Mats Hedberg, Gunilla Bengtsson-Olivecrona, A. Leizorovicz, Lars N. Jorgensen, U. Spannagel, Per Østergaard, Thomas Mätzsch, Tina Au, Ulla Hedner, Graham F. Pineo, Gary E. Raskob, Karl-Gösta Ljungström, Ole Nordfang, Jan Holst, Bengt Lindblad, Jan Frisell, P. Kujath, Qingyu Wu, Robert D. Rosenberg, Per Anders Flordal, P. Østergaard, Ulf Nyman, M.C. Haugh, Peer Wille-Jørgensen, Carlos A. Labarrere, Ulrich Abildgaard, John P. Sheehan, Evan Sadler, Gert Nielsen, Richard D. Kenagy, Page Faulk, Tetsuhito Kojima, Lars C. Borris, Iver Lausen, H. Kristensen, Russell D. Hull, Magnus Hultin, Gwendolyn J. Stewart, Anthony J. Comerota, Joan Dawes, Bertil Friberg, John A. Mclntyre, Alexander W. Clowes, Donald S. Torry, David Bergqvist, Thomas Olivecrona, Trevor W. Barrowcliffe, L.C. Petersen, Olivier Chevreuil, Jens L. Petersen, Jane Wilson, Andrew N. Nicolaides, Monika M. Clowes, Guoqing Liu, Ana Padilla, M.M. Samama, O. Nordfang, Evi Kalodiki, Mira L. Katz, Colin G. Taylor, Dawn R. Wagenknecht, Steven R. Lentz, S. Valentin, V.V. Kakkar, Klas Norrby, Nicholas W. Shworak, Göran Nylander, L. Bara, W. Habscheid, Elaine Gray, Staffan Törngren, Michael R. Lassen, Barry Halliwell, Homayoun Hashemi, Manuel Tsiang

Publikováno v: Pathophysiology of Haemostasis and Thrombosis. 23:I-IV

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d899b8bce2705e1aa0ce01f4f5a48b68
https://doi.org/10.1159/000216902

Zobrazit plný text záznamu

Mechanisms of binding of recombinant extrinsic pathway inhibitor (rEPI) to cultured cell surfaces. Evidence that rEPI can bind to and inhibit factor VIIa-tissue factor complexes in the absence of factor Xa

Autor: O Nordfang, Natalie S. Callander, L. V M Rao, Samuel I. Rapaport, Per Morten Sandset, Bonnie J. Warn-Cramer

Publikováno v: Journal of Biological Chemistry. 267:876-882

Extrinsic pathway inhibitor plays a key role in modulating tissue factor-dependent blood coagulation. We have studied binding of radioiodinated recombinant extrinsic pathway inhibitor (rEPI) to cultured cell surfaces. rEPI in the absence of added rea

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bfbd4cdb116ee52e9ea90caf56f607f0
https://doi.org/10.1016/s0021-9258(18)48365-2

Zobrazit plný text záznamu

Recombinant human extrinsic pathway inhibitor. Production, isolation, and characterization of its inhibitory activity on tissue factor-initiated coagulation reactions

Autor: P M Christensen, Anders H. Pedersen, T C Beck, K B Moeller, F Norris, F C Wiberg, U Hedner, O. Nordfang, K Norris, J Meidahl-Pedersen

Publikováno v: Journal of Biological Chemistry. 265:16786-16793

Previous studies have shown that extrinsic pathway inhibitor (EPI) is an effective inhibitor of factor Xa alone or factor VIIa-tissue factor complex in the presence of factor Xa. Since tissue factor exposure is implicated in thrombogenesis, we hypoth

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d9316afedad0c439e172f9d66f3e8044
https://doi.org/10.1016/s0021-9258(17)44829-0

Zobrazit plný text záznamu

Decline of factor VIII and factor IX inhibitors during long-term treatment with NovoSeven

Autor: M, Johannessen, R B, Andreasen, O, Nordfang

Publikováno v: Blood coagulationfibrinolysis : an international journal in haemostasis and thrombosis. 11(3)

Recombinant factor VIIa (rFVIIa) (NovoSeveng) is used to treat bleeding episodes in hemophilia A and B patients with inhibitor antibodies against factor VIII (FVIII) and factor IX. rFVIIIa has been studied in home treatment of mild-to-moderate joint,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::4bc1d3e85e220a0d03ae2a2b91072a55
https://pubmed.ncbi.nlm.nih.gov/10870803

Zobrazit plný text záznamu

Comparison of the factor VII:C clot analysis and a modified activated factor VII analysis for monitoring factor VII activity in patients treated with recombinant activated factor VII (NovoSeven)

Autor: M. Johannessen, G. Nielsen, O. Nordfang

Publikováno v: Blood coagulationfibrinolysis : an international journal in haemostasis and thrombosis. 11

Bleeding episodes in haemophilia A and B inhibitor patients are now frequently treated with recombinant activated factor VII (NovoSeven®, Novo Nordisk A/S, Bagsvaerd, Denmark). Until now, the FVII:C coagulation assay has been used to monitor NovoSev

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c62072168062831868a4757b5af93a0e
https://pubmed.ncbi.nlm.nih.gov/10850583

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání